US to pay over $1 bn for 100 mn doses of J&J's potential Covid-19 vaccine

The latest contract equates to roughly $10 per vaccine dose produced by J&J
The United States government will pay Johnson & Johnson over $1 billion for 100 million doses of its potential coronavirus vaccine, its latest such arrangement as the race to tame the pandemic intensifies, the drugmaker said on Wednesday.

 
It said it would deliver the vaccine to the Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorization by the US Food and Drug Administration (FDA).

 
J&J has already received $1 billion in funding from the US

 
government - BARDA agreed in March to provide that money for the company to build manufacturing capacity for more than 1 billion doses of the experimental vaccine.

 
The latest contract equates to roughly $10 per vaccine dose produced by J&J. Including the first $1 billion deal with the US government, the price would be slightly higher than the $19.50 per dose that the United States is paying for the vaccine being developed by Pfizer Inc and German biotech BioNTech SE.

 
The US government may also purchase an additional 200 million doses under a subsequent agreement. J&J did not disclose that deal's value.

 
J&J plans to study a one- or two-dose regimen of the vaccine in parallel later this year. A single-shot regimen could allow more people to be vaccinated with the same number of doses and would sidestep issues around getting people to come back for their second dose.

 
This is J&J's first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been reached.

 
J&J's investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early-stage study.

 
There are currently no approved vaccines for Covid-19. More than 20 are in clinical trials.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel